JOURNAL ASMAC No 1 - février 2020

Perspectives
Literatur
1. Hanahan D, Weinberg RA.
Hallmarks of cancer: the next
generation. Cell. 2011; 144: 646 – 74.
2. Wei SC, Duffy CR, Allison
JP. Fundamental Mechanisms of
Immune Checkpoint Blockade
Therapy. Cancer Discov. 2018; 8:
1069 – 86.
3. June CH, Riddell SR,
Schumacher TN. Adoptive cellular
therapy: a race to the finish line.
Sci Transl Med. 2015; 7: 280ps7.
4. van der Burg SH, Arens R,
Ossendorp F, van Hall T, Melief CJ.
Vaccines for established cancer:
overcoming the challenges posed
by immune evasion. Nat Rev
Cancer. 2016; 16: 219 – 33.
5. Chen DS, Mellman I.
Elements of cancer immunity and
the cancer-immune set point.
Nature. 2017; 541: 321 – 30.
6. Rizvi NA, Hellmann MD,
Snyder A, et al. Cancer immunology.
Mutational landscape
determines sensitivity to PD-1
blockade in non-small cell lung
cancer. Science. 2015; 348: 124 – 8.
7. Schumacher TN, Schreiber
RD. Neoantigens in cancer
immunotherapy. Science. 2015;
348: 69 – 74.
8. Dudley JC, Lin MT, Le DT,
Eshleman JR. Microsatellite
Instability as a Biomarker for PD-1
Blockade. Clin Cancer Res. 2016;
22: 813 – 20.
9. Diaz LA, Jr., Le DT. PD-1
Blockade in Tumors with
Mismatch-Repair Deficiency. The
New England journal of medicine.
2015; 373: 1979.
10. Le DT, Uram JN, Wang H,
et al. PD-1 Blockade in Tumors
with Mismatch-Repair Deficiency.
The New England journal of
medicine. 2015; 372: 2509 – 20.
11. Cesano A, Warren S.
Bringing the next Generation of
Immuno-Oncology Biomarkers to
the Clinic. Biomedicines. 2018; 6.
12. Tian L, Goldstein A, Wang
H, et al. Mutual regulation of
tumour vessel normalization and
immunostimulatory reprogramming.
Nature. 2017; 544: 250 – 4.
13. Ramagopal UA, Liu W,
Garrett-Thomson SC, et al.
Structural basis for cancer
immunotherapy by the first-inclass
checkpoint inhibitor
ipilimumab. Proc Natl Acad Sci
USA. 2017; 114: E4223 – E32.
14. Agata Y, Kawasaki A,
Nishimura H, et al. Expression of
the PD-1 antigen on the surface of
stimulated mouse T and B
lymphocytes. Int Immunol. 1996;
8: 765 – 72.
15. Yokosuka T, Takamatsu M,
Kobayashi-Imanishi W, et al.
Programmed cell death 1 forms
negative costimulatory microclusters
that directly inhibit T cell
receptor signaling by re cruiting
phosphatase SHP2. J Exp Med.
2012; 209: 1201 – 17.
16. Hodi FS, O›Day SJ,
McDermott DF, et al. Improved
survival with ipilimumab in
patients with metastatic melanoma.
The New England journal of
medicine. 2010; 363: 711 – 23.
17. Schadendorf D, Hodi FS,
Robert C, et al. Pooled Analysis of
Long-Term Survival Data From
Phase II and Phase III Trials of
Ipilimumab in Unresectable or
Metastatic Melanoma. Journal of
clinical oncology : official journal
of the American Society of Clinical
Oncology. 2015; 33: 1889 – 94.
18. Bernard-Tessier A, Baldini
C, Martin P, et al. Outcomes of
long-term responders to anti-programmed
death 1 and antiprogrammed
death ligand 1 when
being rechallenged with the same
anti-programmed death 1 and
anti-programmed death ligand 1 at
progression. European journal of
cancer. 2018; 101: 160 – 4.
19. Larkin J, Chiarion-Sileni V,
Gonzalez R, et al. Combined
Nivolumab and Ipilimumab or
Monotherapy in Untreated
Melanoma. The New England
journal of medicine. 2015; 373:
23 – 34.
20. Robert C, Schachter J,
Long GV, et al. Pembrolizumab
versus Ipilimumab in Advanced
Melanoma. The New England
journal of medicine. 2015; 372:
2521 – 32.
21. Hodi FS, Chiarion-Sileni V,
Gonzalez R, et al. Nivolumab plus
ipilimumab or nivolumab alone
versus ipilimumab alone in
advanced melanoma (CheckMate
067): 4-year outcomes of a
multicentre, randomised, phase 3
trial. The Lancet Oncology. 2018;
19: 1480 – 92.
22. Tawbi HA, Forsyth PA,
Algazi A, et al. Combined
Nivolumab and Ipilimumab in
Melanoma Metastatic to the Brain.
The New England journal of
medicine. 2018; 379: 722 – 30.
23. Eggermont AMM, Blank
CU, Mandala M, et al. Adjuvant
Pembrolizumab versus Placebo in
Resected Stage III Melanoma. The
New England journal of medicine.
2018; 378: 1789 – 801.
24. Weber J, Mandala M, Del
Vecchio M, et al. Adjuvant
Nivolumab versus Ipilimumab in
Resected Stage III or IV Melanoma.
The New England journal of
medicine. 2017; 377: 1824 – 35.
25. Gandhi L, Rodriguez-Abreu
D, Gadgeel S, et al.
Pembrolizumab plus Chemotherapy
in Metastatic Non-Small-Cell
Lung Cancer. The New England
journal of medicine. 2018; 378:
2078 – 92.
26. Paz-Ares L, Luft A, Vicente
D, et al. Pembrolizumab plus
Chemotherapy for Squamous
Non-Small-Cell Lung Cancer. The
New England journal of medicine.
2018; 379: 2040 – 51.
27. Reck M, Rodriguez-Abreu
D, Robinson AG, et al. Updated
Analysis of KEYNOTE-024:
Pembrolizumab Versus Platinum-Based
Chemotherapy for
Advanced Non-Small-Cell Lung
Cancer With PD-L1 Tumor
Proportion Score of 50 % or
Greater. Journal of clinical
oncology : official journal of the
American Society of Clinical
Oncology. 2019: JCO1800149.
28. Antonia SJ, Villegas A,
Daniel D, et al. Durvalumab after
Chemoradiotherapy in Stage III
Non-Small-Cell Lung Cancer. The
New England journal of medicine.
2017; 377: 1919 – 29.
29. Horn L, Mansfield AS,
Szczesna A, et al. First-Line
Atezolizumab plus Chemotherapy
in Extensive-Stage Small-Cell Lung
Cancer. The New England journal
of medicine. 2018; 379: 2220 – 9.
30. Ko JJ, Xie W, Kroeger N, et
al. The International Metastatic
Renal Cell Carcinoma Database
Consortium model as a prognostic
tool in patients with metastatic
renal cell carcinoma previously
treated with first-line targeted
therapy: a popula tion-based study.
The Lancet Oncology. 2015; 16:
293 – 300.
31. Motzer RJ, Tannir NM,
McDermott DF, et al. Nivolumab
plus Ipilimumab versus Sunitinib
in Advanced Renal-Cell Carcinoma.
The New England journal of
medicine. 2018; 378: 1277 – 90.
32. Motzer RJ, Penkov K,
Haanen J, et al. Avelumab plus
Axitinib versus Sunitinib for
Advanced Renal-Cell Carcinoma.
The New England journal of
medicine. 2019.
33. Rini BI, Plimack ER, Stus
V, et al. Pembrolizumab plus
Axitinib versus Sunitinib for
Advanced Renal-Cell Carcinoma.
The New England journal of
medicine. 2019.
34. Bellmunt J, de Wit R,
Vaughn DJ, et al. Pembrolizumab
as Second-Line Therapy for
Advanced Urothelial Carcinoma.
The New England journal of
medicine. 2017; 376: 1015 – 26.
35. Powles T, Duran I, van der
Heijden MS, et al. Atezolizumab
versus chemotherapy in patients
with platinum-treated locally
advanced or metastatic urothelial
carcinoma (IMvigor211): a multicentre,
open-label, phase 3
randomised controlled trial.
Lancet. 2018; 391: 748 – 57.
36. Sharma P, Retz M,
Siefker-Radtke A, et al. Nivolumab
in metastatic urothelial carcinoma
after platinum therapy (Check Mate
275): a multicentre, single-arm,
phase 2 trial. The Lancet Oncology.
2017; 18: 312 – 22.
37. Kang YK, Boku N, Satoh T,
et al. Nivolumab in patients with
advanced gastric or gastro-oesophageal
junction cancer refractory to,
or intolerant of, at least two
previous chemotherapy regimens
(ONO-4538 – 12, ATTRACTION-2): a
randomised, double-blind,
placebo-controlled, phase 3 trial.
Lancet. 2017; 390: 2461 – 71.
38. T. K. Pembrolizumab
versus chemotherapy as second-line
therapy for advanced
esophageal cancer: Phase III
KEYNOTE-181 study. J Clin Oncol
37, 2019 (suppl 4; abstr 2).
39. Overman MJ, Lonardi S,
Wong KYM, et al. Durable Clinical
Benefit With Nivolumab Plus
Ipilimumab in DNA Mismatch
Repair-Deficient / Microsatellite
VSAO /ASMAC Journal 1/20 37